viewLexaGene Holdings Inc.

LexaGene starts program to Identify UK and South African COVID Sequences

Lexagene Holdings (CVE: LXG- OTCQB: LXXGF) CEO Jack Regan joined Steve Darling from Proactive with news the company is planning to use their patented MiQLa system to investigate novel variants of the SARS-Cov-2 which is the pathogen that causes COVID-19.

Dr. Regan telling Proactive this investigation of the variants becomes very important to make sure vaccines will remain effective as the new strains appear to be about 70% more contagious, making containment that much more challenging.

Quick facts: LexaGene Holdings Inc.

Price: 1.16 CAD

Market: TSX-V
Market Cap: $132.66 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of LexaGene Holdings Inc. named herein, including the promotion by the Company of LexaGene Holdings Inc. in any Content on the Site, the Company...


Lexagene’s MiQLab takes another step forward successfully detecting UK and...

Lexagene Holdings (CVE: LXG- OTCQB: LXXGF) CEO Dr. Jack Regan joined Steve Darling from Proactive with news the company has been able to successfully configure their MiQLab system to detect both the UK and South African variants of COVID-19. Regan says this was able to be done in just two...

2 weeks, 1 day ago

2 min read